Compare Amphastar Pharmaceuticals Inc (AMPH) vs Broadcom Inc (AVGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Broadcom Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Broadcom Inc trades at $416.08 (market cap $2.01T). The key difference: Broadcom Inc is far larger — about 2326.5× Amphastar Pharmaceuticals Inc's market cap, and Broadcom Inc pays a 0.62% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | AVGO | |
|---|---|---|
Market Cap | $863.95M | $2.01T |
Sector | Health | Technology |
52-Week High | $30.81 | $481.57 |
52-Week Low | $16.87 | $289.60 |
Enterprise Value | $1.26B | $2.05T |
Dividend Yield | — | 0.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Broadcom (AVGO) trades at $427.76, up 1.71% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported robust earnings beats, with Q1 2026 EPS of $2.44 exceeding expectations, and AI semiconductor revenue surged 143% year-over-year to $10.8 billion in Q2 2026. Valuation ratios are elevated, with a P/E of 71.17, reflecting high growth expectations.
Outlook remains positive driven by AI demand, with CEO Hock Tan forecasting over $100 billion in AI semiconductor revenue by 2027. Risks include competitive pressures and high debt levels. Analysts are overwhelmingly bullish, with a consensus price target of $510.21, implying 19% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →
